{"id":"sbrt-pd-1-inhibitor-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Rash"},{"rate":"5-20%","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL1474985","moleculeType":"Small molecule","molecularWeight":"476.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SBRT delivers high doses of radiation to specific areas of the body, minimizing damage to surrounding healthy tissue. PD-1 inhibitors, such as those in this combination, work by blocking the PD-1 receptor on T cells, allowing them to recognize and attack cancer cells more effectively. Chemotherapy is used to target rapidly dividing cancer cells and slow tumor growth.","oneSentence":"This combination therapy uses Stereotactic Body Radiation Therapy (SBRT) to target cancer cells, while also inhibiting the PD-1 receptor to enhance the immune response and reduce tumor growth, and chemotherapy to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:37.203Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT06627712","phase":"PHASE3","title":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":318},{"nctId":"NCT06877299","phase":"PHASE2","title":"Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-04","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06121505","phase":"PHASE2","title":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-03-01","conditions":"Lung Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT03767582","phase":"PHASE1, PHASE2","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-12-12","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":46},{"nctId":"NCT07193641","phase":"PHASE2","title":"A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-06-15","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT06691594","phase":"PHASE2","title":"Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02","conditions":"Breast Cancer Invasive","enrollment":20},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT06501378","phase":"PHASE2","title":"Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"NSCLC Stage IV","enrollment":40},{"nctId":"NCT06501391","phase":"PHASE2","title":"Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"NSCLC Stage IV, Brain Metastases","enrollment":54},{"nctId":"NCT06573398","phase":"PHASE2","title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Carcinoma, Pancreatic Ductal","enrollment":20},{"nctId":"NCT06313541","phase":"PHASE2","title":"Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-10","conditions":"NSCLC Stage IV","enrollment":146},{"nctId":"NCT06190782","phase":"PHASE3","title":"Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-09-27","conditions":"Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy","enrollment":354},{"nctId":"NCT05790447","phase":"PHASE2","title":"Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"Advanced Solid Tumor, Refractory Tumor","enrollment":60},{"nctId":"NCT05431764","phase":"PHASE2","title":"Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-20","conditions":"Nasopharyngeal Carcinoma","enrollment":38},{"nctId":"NCT04878107","phase":"PHASE2","title":"SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2022-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":88},{"nctId":"NCT05290194","phase":"PHASE2","title":"Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-03-28","conditions":"Radiotherapy, PD-1 Inhibitor, Capecitabine","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SBRT+PD-1 Inhibitor + Chemotherapy","genericName":"SBRT+PD-1 Inhibitor + Chemotherapy","companyName":"West China Hospital","companyId":"west-china-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses Stereotactic Body Radiation Therapy (SBRT) to target cancer cells, while also inhibiting the PD-1 receptor to enhance the immune response and reduce tumor growth, and chemotherapy to kill rapidly dividing cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}